Last updated on October 2016

Acne, psoriasis, atopic dermatitis


Brief description of study

Acne, psoriasis, atopic dermatitis

Detailed Study Description

A 52-week, multicenter, randomized, double-blind study of secukinumab (300mg) to demonstrate efficacy as assessed by psoriasis area and severity index and investigator's global assessment after 12 weeks of treatment, compared to ustekinumab, and to assess long-term safety, tolerability, and efficacy in subjects with moderate to severe plaque psoriasis.

Clinical Study Identifier: TX145538

Contact Investigators or Research Sites near you

Start Over

Janet Reed

Rivergate Dermatology Clinical Research Center
Goodlettsville, TN USA
  Connect »